Advertisement

Current Gastroenterology Reports

, Volume 14, Issue 5, pp 439–445 | Cite as

Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence

  • Amit H. Sachdev
  • Mark Pimentel
Large Intestine (B Cash, Section Editor)

Abstract

Irritable bowel syndrome (IBS) is the most common gastrointestinal condition effecting adults in developed countries worldwide. Over the last decade, evidence has emerged suggesting that gut bacteria play a role in the pathophysiology of IBS. While difficult to identify using noninvasive means, one of the most common attributable bacterial concepts in IBS is the small intestinal bacterial overgrowth hypothesis (SIBO). In this article, we review the different mechanisms by which gut flora and, specifically, SIBO may contribute to IBS and the evidence supporting the use of various antibiotic therapies in treating IBS.

Keywords

Irritable bowel syndrome Antibiotics Postinfectious irritable bowel syndrome Small intestinal bacterial overgrowth 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982;83(3):529–34.PubMedGoogle Scholar
  2. 2.
    Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79(2):283–8.PubMedGoogle Scholar
  3. 3.
    Thompson WG. The functional gastrointestinal bowel disorders. In: Drossman DA, editor. The functional gastrointestinal disorders. Boston: Little, Brown; 1994. p. 117–34.Google Scholar
  4. 4.
    Whitehead WE. Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am J Med. 1999;107(5A):33S–40S.PubMedCrossRefGoogle Scholar
  5. 5.
    Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl 2:II43–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Pimentel M, Hwang L, Melmed GY, et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig Dis Sci. 2010;55(1):145–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91.PubMedCrossRefGoogle Scholar
  8. 8.
    Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):237–41.PubMedGoogle Scholar
  9. 9.
    Guidelines--Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):307–12Google Scholar
  10. 10.
    Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 1984;87(1):1–7.PubMedGoogle Scholar
  11. 11.
    Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003;349(22):2136–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Ringel Y, Williams RE, Kalilani L, et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1):68–72. quiz 3.PubMedCrossRefGoogle Scholar
  13. 13.
    McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci. 1993;38(10):1773–82.PubMedCrossRefGoogle Scholar
  14. 14.
    McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci. 1993;38(10):1761–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228(2):188–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47(12):2639–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118(5):842–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Manabe N, Tanaka T, Hata J, et al. Pathophysiology underlying irritable bowel syndrome–from the viewpoint of dysfunction of autonomic nervous system activity. J Smooth Muscle Res. 2009;45(1):15–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33(6):825–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Levy RL, Cain KC, Jarrett M, et al. The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome. J Behav Med. 1997;20(2):177–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res. 2008;64(2):119–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44(10):672–5.PubMedCrossRefGoogle Scholar
  23. 23.
    • Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802–8. Provided the first conclusive direct evidence for SIBO in IBS i.e. evidence based on culture of the small bowel rather than breath testing.PubMedCrossRefGoogle Scholar
  24. 24.
    Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with Irritable Bowel Syndrome. Dig Dis Sci. 2012Google Scholar
  25. 25.
    Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–86.PubMedCrossRefGoogle Scholar
  26. 26.
    Shah ED, Basseri RJ, Chong K, et al. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Quigley EM. New perspectives on the role of the intestinal flora in health and disease. J Gastrointestin Liver Dis. 2006;15(2):109–10.PubMedGoogle Scholar
  28. 28.
    Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449(7164):804–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–9.PubMedGoogle Scholar
  32. 32.
    Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(11–12):1157–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52(1):89–95.PubMedGoogle Scholar
  34. 34.
    • Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–42. Important early study demonstrating SIBO in IBS pa#ents and the efficacy of antibiotic (rifaximin) treatment in allevia#ng symptoms.PubMedGoogle Scholar
  35. 35.
    Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326–33.PubMedCrossRefGoogle Scholar
  36. 36.
    • Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. Describes two large phase 3, double‐blind, placebo‐controlled trials (TARGET 1 and TARGET 2) which showed that treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms in patients who had IBS without constipation.PubMedCrossRefGoogle Scholar
  37. 37.
    Lin HC, Pimentel M. Bacterial concepts in irritable bowel syndrome. Rev Gastroenterol Disord. 2005;5 Suppl 3:S3–9.PubMedGoogle Scholar
  38. 38.
    Basseri RJ, Weitsman S, Barlow GM, et al. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY). 2011;7(7):455–93.Google Scholar
  39. 39.
    Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4(11):430–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Macfarlane S, Macfarlane GT. Bacterial diversity in the human gut. Adv Appl Microbiol. 2004;54:261–89.PubMedCrossRefGoogle Scholar
  41. 41.
    Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915–20.PubMedCrossRefGoogle Scholar
  42. 42.
    O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Swidsinski A, Loening-Baucke V, Lochs H, et al. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11(8):1131–40.PubMedGoogle Scholar
  45. 45.
    Gorbach SL, Plaut AG, Nahas L, et al. Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology. 1967;53(6):856–67.PubMedGoogle Scholar
  46. 46.
    Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69(5):1035S–45S.PubMedGoogle Scholar
  48. 48.
    Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177.PubMedCrossRefGoogle Scholar
  49. 49.
    Pimentel M, Chang C. Inflammation and microflora. Gastroenterol Clin North Am. 2011;40(1):69–85.PubMedCrossRefGoogle Scholar
  50. 50.
    Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.PubMedCrossRefGoogle Scholar
  51. 51.
    Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011;130(2):202–12.PubMedCrossRefGoogle Scholar
  52. 52.
    Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691–701.PubMedCrossRefGoogle Scholar
  53. 53.
    Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract. 2010;2010.Google Scholar
  54. 54.
    Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361–80.PubMedCrossRefGoogle Scholar
  55. 55.
    Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37.PubMedCrossRefGoogle Scholar
  57. 57.
    McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr. 1984;39(2):338–42.PubMedGoogle Scholar
  58. 58.
    Pimentel M. Evaluating a bacterial hypothesis in IBS using a modification of Koch’s postulates: part 1. Am J Gastroenterol. 2010;105(4):718–21.PubMedCrossRefGoogle Scholar
  59. 59.
    Mitsuoka T. Recent trends in research on intestinal flora. Bifido Microflora. 1982;1:3–24.Google Scholar
  60. 60.
    Toskes PP. Bacterial overgrowth of the gastrointestinal tract. Adv Intern Med. 1993;38:387–407.PubMedGoogle Scholar
  61. 61.
    Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 2009;19(1):141–50. vii.PubMedCrossRefGoogle Scholar
  62. 62.
    Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.PubMedCrossRefGoogle Scholar
  63. 63.
    Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology. 1984;86(1):174–93.PubMedGoogle Scholar
  64. 64.
    Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Pimentel M, Lezcano S. Irritable bowel syndrome: bacterial overgrowth–what’s known and what to do. Curr Treat Options Gastroenterol. 2007;10(4):328–37.PubMedCrossRefGoogle Scholar
  66. 66.
    Pimentel M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). Gut. 2008;57(9):1334–5. author reply 5.PubMedGoogle Scholar
  67. 67.
    King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology. 1979;76(5 Pt 1):1035–55.PubMedGoogle Scholar
  68. 68.
    Vantrappen G, Janssens J, Hellemans J, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158–66.PubMedCrossRefGoogle Scholar
  69. 69.
    Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol. 2010;16(29):3680–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Khoshini R, Dai SC, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443–54.PubMedCrossRefGoogle Scholar
  71. 71.
    Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55(8):2135–43.PubMedCrossRefGoogle Scholar
  72. 72.
    Kunkel D, Makhani MD, Chong K, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Gastroenterology. 2010;138:S629.CrossRefGoogle Scholar
  73. 73.
    Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297–303.PubMedCrossRefGoogle Scholar
  74. 74.
    Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103(4):958–63.PubMedCrossRefGoogle Scholar
  75. 75.
    Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302–9.PubMedGoogle Scholar
  76. 76.
    Youn YH, Park JS, Jahng JH, et al. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. Dig Dis Sci. 2011;56(7):2059–66.PubMedCrossRefGoogle Scholar
  77. 77.
    Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53(4):982–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther. 2006;24(2):183–205.PubMedCrossRefGoogle Scholar
  80. 80.
    Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998;42(1):42–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161(14):1733–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Cash BD, Chey WD. Advances in the management of irritable bowel syndrome. Curr Gastroenterol Rep. 2003;5(6):468–75.PubMedCrossRefGoogle Scholar
  83. 83.
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15(10):1655–66.PubMedCrossRefGoogle Scholar
  84. 84.
    Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16(11):1877–88.PubMedCrossRefGoogle Scholar
  85. 85.
    Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19–31.PubMedCrossRefGoogle Scholar
  86. 86.
    Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14(1):23–34.PubMedCrossRefGoogle Scholar
  87. 87.
    Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557–63.PubMedGoogle Scholar
  88. 88.
    Lembo A, Zakko SF, Ferreira NL, et al. T1390 Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134(4, Supplement 1):A-545.CrossRefGoogle Scholar
  89. 89.
    Van Citters GW, Lin HC. Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2005;7(4):317–20.PubMedCrossRefGoogle Scholar
  90. 90.
    Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169–74.PubMedCrossRefGoogle Scholar
  91. 91.
    Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia. 1984;3(6):365–7.PubMedGoogle Scholar
  92. 92.
    Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3(2):201–11.PubMedCrossRefGoogle Scholar
  93. 93.
    Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity–a review. Chemotherapy. 2005;51 Suppl 1:67–72.PubMedCrossRefGoogle Scholar
  94. 94.
    Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993;16(2):111–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Ripa S, Mignini F, Prenna M, et al. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res. 1987;13(8):483–8.PubMedGoogle Scholar
  96. 96.
    Sierra JM, Navia MM, Vargas M, et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother. 2001;47(6):904–5.PubMedCrossRefGoogle Scholar
  97. 97.
    Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14(5):551–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22(1):31–5.PubMedCrossRefGoogle Scholar
  99. 99.
    Pimentel M, Park S, Kane SV, et al. Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Ann Intern Med. 2006;145:557–63.PubMedGoogle Scholar
  100. 100.
    • Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56(7):2067–72. Demonstrated that for subjects with nonconstipated IBS, retreatment with rifaximin was successful up to five times with no significant reduction in benefit, or of duration of benefit, for successive retreatments. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.GI Motility LaboratoryCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations